Evidence map›Paper›PMID 32272101›Full record

ArticleThe American journal of medicine2020

Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.

Phillip H Lam, Milton Packer, Gauravpal S Gill, Wen-Chih Wu, Wayne C Levy, Michael R Zile, Vijaywant Brar, Cherinne Arundel, Yan Cheng, Steven N Singh and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 1 country.

Phillip H LamVeterans Affairs Medical Center, Washington, DC; MedStar Washington Hospital Center, Washington, DC; Georgetown University, Washington, DC.
Milton PackerBaylor University Medical Center, Dallas, TX.
Gauravpal S GillVeterans Affairs Medical Center, Washington, DC; MedStar Washington Hospital Center, Washington, DC; Georgetown University, Washington, DC.
Wen-Chih WuBrown University, Providence, RI; Veterans Affairs Medical Center, Providence, RI.
Wayne C LevyUniversity of Washington, Seattle, WA.
Michael R ZileMedical University of South Carolina, Charleston, SC; Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC.
Vijaywant BrarMedStar Washington Hospital Center, Washington, DC; Georgetown University, Washington, DC.
Cherinne ArundelVeterans Affairs Medical Center, Washington, DC; Georgetown University, Washington, DC; George Washington University, Washington, DC.
Yan ChengVeterans Affairs Medical Center, Washington, DC; George Washington University, Washington, DC.
Steven N SinghVeterans Affairs Medical Center, Washington, DC; Georgetown University, Washington, DC.
Richard M AllmanGeorge Washington University, Washington, DC; University of Alabama at Birmingham, Birmingham, AL.
Gregg C FonarowUniversity of California, Los Angeles, CA.
Ali AhmedVeterans Affairs Medical Center, Washington, DC; Georgetown University, Washington, DC; George Washington University, Washington, DC. Electronic address: ali.ahmed@va.gov.
Georgetown University · USMedStar Washington Hospital Center · USGeorge Washington University · USBaylor University Medical Center · USMedical University of South Carolina · USProvidence College · USUniversity of California, Los Angeles · USUniversity of Washington · US

Funding

Heart failure, chronic kidney disease, and renin-angiotensin system inhibitionR01HL085561 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AHMED, ALI · 2006 to 2009
$1.5M
Neurohormonal Blockade and Outcomes in Diastolic Heart FailureR01HL097047 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AHMED, ALI · 2009 to 2010
$915k
Group Medical Visits in Heart Failure for Post-Hospitalization Follow-UpI01HX001800 · VA · PROVIDENCE VA MEDICAL CENTER · PI WU, WEN-CHIH · 2015 to 2020
–
HSRD VA I01 HX001800HSRD VA I01 HX002422NHLBI NIH HHS R01 HL085561NHLBI NIH HHS R01 HL097047
6 · The paper itself

Abstract

backgroundDigoxin reduces the risk of heart failure hospitalization in patients with heart failure with reduced ejection fraction. Less is known about this association in patients with heart failure with preserved ejection fraction (HFpEF), the examination of which was the objective of the current study.

methodsIn the Medicare-linked OPTIMIZE-HF registry, 7374 patients hospitalized for HF had ejection fraction ≥50% and were not receiving digoxin prior to admission. Of these, 5675 had a heart rate ≥50 beats per minute, an estimated glomerular filtration rate ≥30 mL/min/1.73 m

resultsAmong the 1026 matched patients with HFpEF, 30-day heart failure readmission occurred in 6% and 9% of patients initiated and not initiated on digoxin, respectively (HR 0.70; 95% CI, 0.45-1.10; P = .124). HRs (95% CIs) for 30-day all-cause readmission and all-cause mortality associated with digoxin initiation were 0.95 (0.73-1.23; P = .689) and 0.93 (0.55-1.56; P = .773), respectively. Digoxin initiation had no association with 6-year outcomes.

conclusionDigoxin initiation prior to hospital discharge was not associated with 30-day or 6-year outcomes in older hospitalized patients with HFpEF.

Indexed as

MortalityStroke VolumeAdrenergic beta-AntagonistsAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAnti-Arrhythmia AgentsAnticoagulantsAtrial FibrillationCardiotonic AgentsCause of DeathDigoxinFemaleHeart FailureHospitalizationAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAnti-Arrhythmia AgentsAnticoagulantsCardiotonic AgentsDigoxinHydroxymethylglutaryl-CoA Reductase InhibitorsMineralocorticoid Receptor AntagonistsPlatelet Aggregation InhibitorsSodium Potassium Chloride Symporter InhibitorsWarfarinDigoxinHeart failure with preserved ejection fractionMortalityReadmission

Identifiers

PMID32272101
PMCPMC10463778
OpenAlexW3014404577

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.